Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct:36:553-562.
doi: 10.1016/j.ebiom.2018.09.005. Epub 2018 Sep 14.

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Sainan An  1 , Liwu Fu  2
Affiliations
Review

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Sainan An et al. EBioMedicine. 2018 Oct.

Abstract

There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. Recently, small-molecule PROTACs with high potency have been frequently reported. In this review, we summarize the emerging characteristics of small-molecule PROTACs, such as inducing a rapid, profound and sustained degradation, inducing a robust inhibition of downstream signals, displaying enhanced target selectivity, and overcoming resistance to small molecule inhibitors. In tumor xenografts, small-molecule PROTACs can significantly attenuate tumor progression. In addition, we also introduce recent developments of the PROTAC technology such as homo-PROTACs. The outstanding advantages over traditional small-molecule drugs and the promising preclinical data suggest that small-molecule PROTAC technology has the potential to greatly promote the development of targeted therapy drugs.

Keywords: E3 ligases; Induced protein degradation; PROTAC; Targeted therapy drugs; Ubiquitin-proteasome system.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overview of the mechanisms of small molecule inhibitors and PROTACs (a) In order to inhibit the activities of target proteins, small molecule inhibitors competitively bind to active sites on the target proteins. The limitations on developing and taking small molecule drugs are shown in this figure. (b) Heterobifunctional PROTAC molecules harness the ubiquitin proteasome system to selectively degrade target proteins. Currently, the generation of PROTACs relies on available small molecular inhibitors to be used as target binding ligands. Alternatively, PROTACs can bind to any crevice on the surface of the target proteins to induce their degradation.
Fig. 2
Fig. 2
Characteristics of PROTACs (a) Protein-protein interactions (PPIs) between the target protein and the E3 ligase can stabilize the target:PROTAC:E3 complex even when the affinity between the target and the PROTAC is weak. The formation of stable ternary complexes is required for the induced protein degradation. (b) A hook effect shows when the systemic concentration of PROTACs is too high. High concentrations of dimeric PROTAC:E3 and PROTAC:target complexes inhibit the formation of degradation-inducing ternary complexes.
Fig. 3
Fig. 3
Other modalities of PROTACs (a) Homo-PROTACs are bivalent small-molecules that can trigger the dimerization of an E3 ligase and its subsequent self-degradation. (b) In contrast to typical PROTACs, general PROTACs cross-link E3 ligases and tagged fusion proteins and subsequently degrade fusion proteins. General PROTACs can be flexibly utilized to degrade variable proteins and study the functions of particular proteins. (c) Through bio-orthogonal click combination of two tagged small molecule precursors, heterobifunctional PROTACs can be formed intracellularly and successfully induce the degradation of target proteins. This approach was created to overcome the high molecular weight nature of typical PROTACs which contain two small-molecule ligands and a linker.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lavanya V., Mohamed Adil A.A., Neesar A., Arun K.R., Shazia J. Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Ther. 2014;1
    1. Wu P., Nielsen T.E., Clausen M.H. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today. 2016;21:5–10. - PubMed
    1. Toure M., Crews C.M. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed Engl. 2016;55:1966–1973. - PubMed
    1. Graves L.M., Duncan J.S., Whittle M.C., Johnson G.L. The dynamic nature of the kinome. Biochem J. 2013;450:1–8. - PMC - PubMed
    1. Gechijian L.N., Buckley D.L., Lawlor M.A., Reyes J.M., Paulk J., Ott C.J. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol. 2018;14:405–412. - PMC - PubMed